Contact Us
Company Overview
|
Pipeline / Clinical Trials
|
Science & Discovery
|
Business Development
|
Investors
Overview
|
Stock Data
|
Governance
|
SEC Filings
|
News & Events
|
Presentations
|
Fundamentals
|
Information Request
Press Release Archive
Press Release Archive
2010
>
2009
>
2008
>
2007
>
2006
> 2005 >
2004
>
2003
>
2002
>
2001
September 6, 2005
RegeneRx to Present at the 3rd Annual ThinkEquity Growth Conference
July 13, 2005
RegeneRx Biopharmaceuticals Joins New Russell Microcap
TM
Index
July 12, 2005
Key European Patent Granted for RegeneRx's Wound Healing Technology
July 12, 2005
Scientists Report RegeneRx's Tß4 Decreases Inflammation And Restores Corneal Clarity After Eye Injury
May 19, 2005
NIH Scientist Reports Wound Healing Effects of Tß4
May 3, 2005
RegeneRx Adds Dr. Gabriel Sosne to Medical and Scientific Advisory Board
May 2, 2005
RegeneRx's Tß4 Subject of Four Presentations at 2005 ARVO Meeting
April 19, 2005
RegeneRx Names Executive Director, Regulatory Affairs
April 18, 2005
RegeneRx Names Chief Financial Officer
April 15, 2005
Scientist Reports RegeneRx's Tß4
Modulates Wound Healing Enzyme
April 8, 2005
RegeneRx Rings the AMEX Opening Bell
March 31, 2005
RegeneRx Reports 2004 Year-End Results
March 21, 2005
RegeneRx Listed on American Stock Exchange
February 28, 2005
RegeneRx Cleared to Initiate Phase II Clinical Trial With Tß4 for Epidermolysis Bullosa
February 25, 2005
RegeneRx President Updates Investment Community at BIO CEO & Investor Conference
February 23, 2005
RegeneRx to Present at BIO’s 2005 CEO & Investor Conference on February 24th
January 18, 2005
RegeneRx's Tß4 Subject of Phase II Clinical Trial In Europe for Venous Stasis Ulcers
January 12, 2005
Wall Street Reporter Interviews RegeneRx CEO
January 10, 2005
RegeneRx Completes $5.86 Million Private Placement
January 3, 2005
RegeneRx Closes on First Tranche of $5.86 Million Private Placement
home
|
Contact Us
|
Resources
|
Site Map
|
Search
